alexa Abstract | Serum Levels of Endothelial Monocyte-Activating Polypeptide-II in Hepatitis C Patients
ISSN: 1745-7580

Immunome Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Objectives: Endothelial monocyte-activating polypeptide-II (EMAP-II) is a cytokine with pro-inflammatory and immune-suppressive properties. The goal of this study was to assess serum EMAP-II in treated and untreated Hepatitis C virus (HCV) patients. Furthermore, we determined the relationship between serum EMAP-II levels with the clinic pathological and laboratory parameters in patients with HCV. Methods: 25 control patients (Group I), 25 treated HCV patients (Group II) and 25 newly diagnosed, untreated patients with HCV (Group III) were included in this study. Serum EMAP-II levels were detected by Enzyme linked immunosorbent assay (ELISA), and HCV RNA was assessed by real time-PCR (RT-PCR). The results were evaluated against clinical and laboratory data. Results: Serum EMAP-II levels were significantly elevated in newly diagnosed, untreated HCV patients compared to treated HCV and control patients (p<0.001). We found that serum EMAP-II levels correlated positively with HCV RNA in untreated HCV patients (p<0.001). While serum albumin and platelet count correlated negatively with serum EMAP-II levels (p<0.001), a positive correlation was observed between EMAP-II and serum bilirubin (p<0.001). Conclusions: Increased serum EMAP-II levels are present in newly diagnosed HCV patients compared to treated HCV and control patients, suggesting EMAP-II as a novel biomarker for HCV diagnosis.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Manal Mohamed Saber and Matthias Clauss


Hepatitis C virus (HCV), Endothelial monocyteactivating polypeptide-II (EMAP-II), Hepatitis C virus (HCV), Endothelial monocyteactivating polypeptide-II (EMAP-II)

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version